{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:38:50Z","timestamp":1745469530963,"version":"3.40.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jacadv.2025.101612","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:04:24Z","timestamp":1742213064000},"page":"101612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pericardial Effusion Associated With Direct Oral Anticoagulant Use in a Single\u00a0Center Experience"],"prefix":"10.1016","volume":"4","author":[{"given":"Jessica","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Jaradeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Deluna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajkumar J.","family":"Sevak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan X.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jacadv.2025.101612_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jacadv.2025.101612_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jacadv.2025.101612_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2025.101612_bib4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jacadv.2025.101612_bib5","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jacadv.2025.101612_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101612_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jacadv.2025.101612_bib8","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101612_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101612_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/heartjnl-2022-321377","article-title":"Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019)","volume":"109","author":"Joy","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.jacadv.2025.101612_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2014.12.062","article-title":"Pericardial bleeding risk with non-vitamin K oral anticoagulants: a meta-analysis","volume":"182","author":"Caldeira","year":"2015","journal-title":"Int J Cardiol"},{"issue":"7-8","key":"10.1016\/j.jacadv.2025.101612_bib12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1345\/aph.1R112","article-title":"Hemopericardium and cardiac tamponade associated with dabigatran use","volume":"46","author":"Dy","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101612_bib13","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1002\/j.1875-9114.2012.01036.x","article-title":"Hemopericardium in a patient treated with dabigatran etexilate","volume":"32","author":"Barton","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101612_bib14","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1002\/phar.1474","article-title":"Isolated hemopericardium associated with rivaroxaban: first case report","volume":"34","author":"Shivamurthy","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101612_bib15","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4081\/cp.2019.1096","article-title":"Isolated hemopericardium after initiation of rivaroxaban: implications and potential mechanisms","volume":"9","author":"Mehta","year":"2019","journal-title":"Clin Pract"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101612_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.14740\/cr902","article-title":"Spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban","volume":"10","author":"Cinelli","year":"2019","journal-title":"Cardiol Res"},{"issue":"7","key":"10.1016\/j.jacadv.2025.101612_bib17","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1002\/phar.1602","article-title":"Spontaneous hemopericardium in a patient receiving apixaban therapy: first case report","volume":"35","author":"Sigawy","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101612_bib18","first-page":"342","article-title":"Spontaneous hemopericardium complicated with hemothorax in a patient receiving edoxaban therapy: a case report","volume":"35","author":"Tsai","year":"2019","journal-title":"Acta Cardiol Sin"},{"issue":"11S","key":"10.1016\/j.jacadv.2025.101612_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.carrev.2019.04.002","article-title":"Hemorrhagic cardiac tamponade associated with apixaban: a case report and systematic review of literature","volume":"20","author":"Asad","year":"2019","journal-title":"Cardiovasc Revascularization Med"},{"key":"10.1016\/j.jacadv.2025.101612_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.carrev.2021.09.010","article-title":"Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review","volume":"39","author":"Sheikh","year":"2022","journal-title":"Cardiovasc Revascularization Med"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101612_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.hrcr.2017.11.015","article-title":"First reported case series in the United States of hemopericardium in patients on apixaban","volume":"4","author":"Sablani","year":"2018","journal-title":"HeartRhythm Case Rep"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101612_bib22","first-page":"430","article-title":"Cardiac tamponade in patients treated with direct oral anticoagulants","volume":"25","author":"Gabarin","year":"2023","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101612_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.echo.2013.06.023","article-title":"American society of echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the society for cardiovascular magnetic resonance and society of cardiovascular computed tomography","volume":"26","author":"Klein","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101612_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/1570161120666220721094739","article-title":"Prognostic value of pericardial effusion size in patients with acute heart failure","volume":"20","author":"Zhai","year":"2022","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101612_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2025.101612_bib26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week","volume":"75","author":"Wiggins","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.jacadv.2025.101612_bib27","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101612_bib28","article-title":"Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series","volume":"1","author":"Nassif","year":"2017","journal-title":"Eur Heart J Case Rep"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101612_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101612_bib30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaccao.2021.07.003","article-title":"Direct oral anticoagulants in patients with cancer and nonvalvular atrial fibrillation","volume":"3","author":"Davis","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101612_bib31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0002-8703(00)90026-7","article-title":"Pericardial and pleural effusions in decompensated chronic heart failure","volume":"139","author":"Kataoka","year":"2000","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101612_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2459\/JCM.0000000000000720","article-title":"Is pericardial effusion a negative prognostic marker? Meta-analysis of outcomes of pericardial effusion","volume":"20","author":"De Filippo","year":"2019","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"13","key":"10.1016\/j.jacadv.2025.101612_bib33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jacadv.2025.101612_bib34","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jacadv.2025.101612_bib35","article-title":"Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants","volume":"34","author":"Shurrab","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101612_bib36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jfma.2023.02.012","article-title":"Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation","volume":"122","author":"Lin","year":"2023","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.jacadv.2025.101612_bib37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.10.031","article-title":"Association between concurrent use of amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation","volume":"186","author":"Shurrab","year":"2023","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101612_bib38","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacadv.2025.101612_bib41","doi-asserted-by":"crossref","first-page":"i2868","DOI":"10.1136\/bmj.i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Jaspers","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101612_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","article-title":"Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation","volume":"133","author":"Piccini","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101612_bib43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacadv.2025.101612_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9511499","article-title":"To measure or not to measure: direct oral anticoagulant laboratory assay monitoring in clinical practice","volume":"2023","author":"Ahuja","year":"2023","journal-title":"Adv Hematol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:56:18Z","timestamp":1745438178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2772963X25000298"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101612","relation":{},"ISSN":["2772-963X"],"issn-type":[{"type":"print","value":"2772-963X"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pericardial Effusion Associated With Direct Oral Anticoagulant Use in a Single\u00a0Center Experience","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101612"}}